Publication | Closed Access

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

Breast OncologyMedicineGynecologyBreast CancerTriple-negative Breast CancerOvarian CarcinomaCancer TreatmentPhase 2OncologyRadiation OncologyGynecology OncologyOvarian Cancer